NASDAQ: $DYAI Dyadic International Inc. provided second quarter 2024 operational and financial results in a press release on August 13, 2024, filed its Form 10-Q with the SEC and held a conference call with investors. Since the last quarterly update, Dyadic announced a development and commercialization partnership with Iowa-based Proliant Health and Biologicals to sell animal-free recombinant albumin products produced by C1. It also signed another deal with a top 10 global dairy company for development of non-animal alpha-lactalbumin. Management attended several industry, trade and investor conferences in June updating stakeholders on recent progress. https://finance.yahoo.com/news/dyai-product-r...00332.html

#nasdaq #stockstowatch #stockstobuy #DYAI @charles